Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy

Zong,Jinbao; Wang,Changyuan; Liu,Bin; Liu,Mingjun; Cao,Yongxian; Sun,Xiufang; Yao,Yuan; Sun,Guirong

doi:10.3892/or.2013.2445

Human hsp70 and HPV16 oE7 fusion protein vaccine induces an effective antitumor efficacy

Authors:
- Jinbao Zong
- Changyuan Wang
- Bin Liu
- Mingjun Liu
- Yongxian Cao
- Xiufang Sun
- Yuan Yao
- Guirong Sun
View Affiliations

Affiliations: Clinical Laboratory, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Dermatology, Qingdao Municipal Hospital, Qingdao 266001, P.R. China, Department of Rheumatology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China
Published online on: May 9, 2013 https://doi.org/10.3892/or.2013.2445
Pages: 407-412

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The persistent infection by human papilloma virus (HPV) is considered to be the major risk factor of cervical cancer, which is one of the most common cancers in women worldwide. Millions of women are currently infected with high-risk HPV. Thus, it is urgent to develop therapeutic vaccines to eliminate established infection or HPV-related diseases. In the present study, we constructed a very promising therapeutic HPV16 protein vaccine of optimized E7 (oE7)/huhsp70 using human hsp70 linked to HPV16 oE7. Our results demonstrated that vaccination with the oE7/huhsp70 protein vaccine induced a very strong E7-specific CD8+ T cell immune response and resulted in a significant therapeutic effect against E7-expressing tumor cells. Our study verifies that huhsp70 is an effective immune adjuvant in the development of tumor therapeutic protein vaccines, and emphasizes that homologous huhsp70 is a promising tool in future human clinical applications.

View Figures

View References

1	Clifford GM, Smith JS, Plummer M, et al: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 88:63–73. 2003. View Article : Google Scholar : PubMed/NCBI
2	Siddiqui MA and Perry CM: Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs. 66:1263–1273. 2006. View Article : Google Scholar : PubMed/NCBI
3	Crosbie EJ and Kitchener HC: Cervarix™-a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. Expert Opin Biol Ther. 7:391–396. 2007.
4	Dell G and Gaston K: Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci. 58:1923–1942. 2001. View Article : Google Scholar : PubMed/NCBI
5	zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002.PubMed/NCBI
6	Li YL, Liu J, Liu JN, et al: Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice. Vaccine. 29:5959–5962. 2011. View Article : Google Scholar : PubMed/NCBI
7	de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, et al: A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother. 61:1485–1492. 2012.PubMed/NCBI
8	Zhou L, Zhu T, Ye X, et al: Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70. Hum Gene Ther. 21:109–119. 2010. View Article : Google Scholar
9	Peng S, Monie A, Pang X, et al: Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci. 8:18–21. 2011.PubMed/NCBI
10	Santin AD, Hermonat PL, Ravaggi A, et al: Induction of human papillomavirus-specific CD4 and CD8 lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol. 73:5402–5410. 1999.
11	Kim D, Hoory T, Wu TC, et al: Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4⁺ T cell. Hum Gene Ther. 18:1129–1139. 2007. View Article : Google Scholar : PubMed/NCBI
12	Hauser H and Chen SY: Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods. 31:225–231. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ma B, Xu YJ, Hung CF, et al: HPV and therapeutic vaccines: Where are we in 2010? Curr Cancer Ther Rev. 6:81–103. 2010. View Article : Google Scholar
14	Maecker HT, Ghanekar SA, Suni MA, et al: Factors affecting the efficiency of CD8⁺ T cell cross-priming with exogenous antigens. J Immunol. 166:7268–7275. 2001. View Article : Google Scholar : PubMed/NCBI
15	Bendz H, Ruhland SC, Pandya MJ, et al: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem. 282:31688–31702. 2007. View Article : Google Scholar
16	Brodsky JL and Chiosis G: Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem. 6:1215–1225. 2006. View Article : Google Scholar : PubMed/NCBI
17	Calderwood SK, Theriault JR and Gong J: Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol. 35:2518–2527. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lancaster GI and Febbraio MA: Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem. 280:23349–23355. 2005. View Article : Google Scholar : PubMed/NCBI
19	Binder RJ and Srivastava PK: Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8⁺ T cells. Nat Immunol. 6:593–599. 2005.PubMed/NCBI
20	Binder RJ, Blachere NE and Srivastava PK: Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem. 276:17163–17171. 2001. View Article : Google Scholar
21	Tobian AA, Canaday DH, Boom WH, et al: Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8⁺ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J Immunol. 172:5277–5286. 2004. View Article : Google Scholar : PubMed/NCBI
22	Delneste Y, Magistrelli G, Gauchat J, et al: Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 17:353–362. 2002. View Article : Google Scholar : PubMed/NCBI
23	Asea A, Kraeft SK, Kurt-Jones EA, et al: HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 6:435–442. 2000. View Article : Google Scholar : PubMed/NCBI
24	Singh-Jasuja H, Scherer HU, Hilf N, et al: The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol. 30:2211–2215. 2000. View Article : Google Scholar : PubMed/NCBI
25	Kuppner MC, Gastpar R, Gelwer S, et al: The role of heat shock protein (hsp70) in dendritic cell maturation: hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur J Immunol. 31:1602–1609. 2001. View Article : Google Scholar : PubMed/NCBI
26	Zong JB, Peng QL, Wang QY, et al: Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8⁺ T cell responses and anti-tumor effects. Oncol Rep. 22:953–961. 2009.PubMed/NCBI
27	Van Doorslaer K, Reimers LL, Studentsov YY, et al: Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol. 116:208–212. 2010.PubMed/NCBI
28	Srivastava P: Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2:185–194. 2002. View Article : Google Scholar : PubMed/NCBI
29	Stewart GR and Young DB: Heat-shock proteins and the host-pathogen interaction during bacterial infection. Curr Opin Immunol. 16:506–510. 2004. View Article : Google Scholar : PubMed/NCBI
30	Segal BH, Wang XY, Dennis CG, et al: Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today. 11:534–540. 2006. View Article : Google Scholar : PubMed/NCBI
31	Harmala LA, Ingulli EG, Curtsinger JM, et al: The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8⁺ T cells in vivo. J Immunol. 169:5622–5629. 2002.
32	Li Y, Subjeck J, Yang G, et al: Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine. 24:5360–5370. 2006. View Article : Google Scholar : PubMed/NCBI
33	Ma JH, Sui YF, Ye J, et al: Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother. 54:907–914. 2005. View Article : Google Scholar : PubMed/NCBI
34	van Eden W, Koets A, van Kooten P, et al: Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine. 21:897–901. 2003.PubMed/NCBI
35	Rook GA, Martinelli R and Brunet LR: Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr Opin Allergy Clin Immunol. 3:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
36	Salvetti M, Ristori G, Buttinelli C, et al: The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J Neuroimmunol. 65:143–153. 1996. View Article : Google Scholar